Standard Injections Versus Reduced Injections for Intravesical onabotulinumtoxinA Treatment of Overactive Bladder
Status:
Recruiting
Trial end date:
2021-12-31
Target enrollment:
Participant gender:
Summary
OnabotulinumtoxinA is an effective treatment for both idiopathic and neurogenic overactive
bladder and was FDA approved for this indication in 2013. The standard technique for
injecting onabotulinumtoxinA into the detrusor is mixing 100 units of onabotulinumtoxinA into
10mL of injectable normal saline and injecting 20 sites with 0.5mL in the posterior wall of
hte bladder for idiopathic overactive bladder and mixing 200 units into 30mL and injecting 30
sites with 1mL for neurogenic overactive bladder. The purpose of this study is to compare the
efficacy of a technique using a reduced number of injections with the same dosage of
onabotulinumtoxinA to the standard technique. The hypothesis is that the reduced technique
will not be inferior in terms of efficacy as the standard technique and that there will be a
lower incidence of urinary tract infections and urinary retention requiring catheterization
post-procedure.